4th Quarter - Report

WALGREEN COMPANY for WALGREEN COMPANY

Period 4th Quarter 2019 Filed Jan 20, 2020 Signed by G. Joel Baise, Director, Government Relations

Official filing
Firm
WALGREEN COMPANY
Client
WALGREEN COMPANY
Income
—
Expenses
$510,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

H.R. 1034 and S.B. 640 (the Phair Pricing Act); provisions related to lowering drug prices and reducing Out-of-Pocket costs to seniors. S.B. 2543 (Prescription Drug Pricing Reduction Act of 2019) provisions related to lowering drug prices and reducing Out-of-Pocket costs to seniors. H.R. 3 (The Elijah E. Cummings Lower Drug Costs Now Act) provisions related to lowering drug prices and reducing Out-of-Pocket costs to seniors.

LobbyistCovered position, as disclosed
ALETHIA JACKSON —
EDWARD KALETA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1034 (116th), H.R. 3 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.